Economic evaluation of the TriageHF Plus clinical pathway for device-based remote monitoring in heart failure.

IF 4.4 2区医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS

Heart Pub Date : 2026-08-25 DOI:10.1136/heartjnl-2025-326702

Fozia Z Ahmed, Rachel Harwood, David Lanctin, Catherine Leonard, Sarah Medland, Daniela Afonso, Stuart Mealing, Toni Weldon, Callum Blunt, Niall G Campbell, Joanne K Taylor

{"title":"Economic evaluation of the TriageHF Plus clinical pathway for device-based remote monitoring in heart failure.","authors":"Fozia Z Ahmed, Rachel Harwood, David Lanctin, Catherine Leonard, Sarah Medland, Daniela Afonso, Stuart Mealing, Toni Weldon, Callum Blunt, Niall G Campbell, Joanne K Taylor","doi":"10.1136/heartjnl-2025-326702","DOIUrl":null,"url":null,"abstract":"Background: In 2024, the UK National Institute of Health and Care Excellence (NICE) recommended TriageHF alerts as an option for remote monitoring of patients with heart failure (HF) and a compatible cardiac implantable electronic device (CIED). Data on the cost-effectiveness of this approach has not been published. This research evaluates the cost-effectiveness of TriageHF Plus in public hospital settings, using data from the TriageHF Plus multicentre study (758 participants, NCT04177199).Methods: An economic model was developed to capture the lifetime cost and benefits of TriageHF Plus versus usual care, based on a site of 300 eligible patients. Analysis on individual patient-level data informed model efficacy and resource use parameters. EuroQol five-dimensional questionnaire data and unit costs were obtained from published, peer-reviewed literature and national databases respectively. Costs and benefits were discounted at 3.5% per annum to adjust future costs and benefits to present value.Results: In a site size of 300, TriageHF Plus was predicted to prevent 384 (363-405) hospitalisations over 5 years. In total, TriageHF Plus saved £3989 (£1812-£5563) per person-lifetime versus usual care and was more effective and cost-saving in 99.4% of simulations. Results were robust to changes in key input parameters. Modelling showed that to avoid one hospitalisation, 1.7 people would need lifetime access to TriageHF Plus.Conclusion: The TriageHF Plus pathway is cost-effective for the remote monitoring of HF in patients with CIEDs.Trial registration number: NCT04177199.","PeriodicalId":12835,"journal":{"name":"Heart","volume":" ","pages":"1022-1032"},"PeriodicalIF":4.4000,"publicationDate":"2026-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13539856/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Heart","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1136/heartjnl-2025-326702","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

Abstract

Background: In 2024, the UK National Institute of Health and Care Excellence (NICE) recommended TriageHF alerts as an option for remote monitoring of patients with heart failure (HF) and a compatible cardiac implantable electronic device (CIED). Data on the cost-effectiveness of this approach has not been published. This research evaluates the cost-effectiveness of TriageHF Plus in public hospital settings, using data from the TriageHF Plus multicentre study (758 participants, NCT04177199).

Methods: An economic model was developed to capture the lifetime cost and benefits of TriageHF Plus versus usual care, based on a site of 300 eligible patients. Analysis on individual patient-level data informed model efficacy and resource use parameters. EuroQol five-dimensional questionnaire data and unit costs were obtained from published, peer-reviewed literature and national databases respectively. Costs and benefits were discounted at 3.5% per annum to adjust future costs and benefits to present value.

Results: In a site size of 300, TriageHF Plus was predicted to prevent 384 (363-405) hospitalisations over 5 years. In total, TriageHF Plus saved £3989 (£1812-£5563) per person-lifetime versus usual care and was more effective and cost-saving in 99.4% of simulations. Results were robust to changes in key input parameters. Modelling showed that to avoid one hospitalisation, 1.7 people would need lifetime access to TriageHF Plus.

Conclusion: The TriageHF Plus pathway is cost-effective for the remote monitoring of HF in patients with CIEDs.

Trial registration number: NCT04177199.

查看原文本刊更多论文

TriageHF Plus用于心衰患者器械远程监测临床途径的经济评价

背景：在2024年，英国国家健康与护理卓越研究所（NICE）推荐TriageHF警报作为远程监测心力衰竭（HF）患者和兼容心脏植入式电子设备（CIED）的一种选择。关于这种方法的成本效益的数据尚未公布。本研究利用TriageHF Plus多中心研究（758名参与者，NCT04177199）的数据，评估了TriageHF Plus在公立医院环境中的成本效益。方法：基于300名符合条件的患者，开发了一个经济模型，以捕捉TriageHF Plus与常规护理相比的终身成本和收益。个体患者层面的数据分析告知模型疗效和资源使用参数。EuroQol五维问卷数据和单位成本分别来自已发表的、同行评议的文献和国家数据库。成本和收益按每年3.5%折现，以调整未来成本和收益的现值。结果：在300个站点中，TriageHF Plus预计在5年内可预防384例（363-405例）住院。总的来说，TriageHF Plus与常规护理相比，每人一生节省了3989英镑（1812- 5563英镑），并且在99.4%的模拟中更有效，更节省成本。结果对关键输入参数的变化具有鲁棒性。模型显示，为了避免一次住院，1.7人将需要终身使用TriageHF Plus。结论：TriageHF Plus路径对于cied患者的HF远程监测具有成本效益。试验注册号：NCT04177199。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Heart 医学-心血管系统

CiteScore

10.30

自引率

5.30%

发文量

320

审稿时长

3-6 weeks

期刊介绍： Heart is an international peer reviewed journal that keeps cardiologists up to date with important research advances in cardiovascular disease. New scientific developments are highlighted in editorials and put in context with concise review articles. There is one free Editor’s Choice article in each issue, with open access options available to authors for all articles. Education in Heart articles provide a comprehensive, continuously updated, cardiology curriculum.